Literature DB >> 11259572

Blockade of currents by the antimalarial drug chloroquine in feline ventricular myocytes.

J A Sánchez-Chapula1, E Salinas-Stefanon, J Torres-Jácome, D E Benavides-Haro, R A Navarro-Polanco.   

Abstract

The effects of the antimalarial drug chloroquine on cardiac action potential and membrane currents were studied at clinically relevant concentrations. In cat Purkinje fibers, chloroquine at concentrations of 0.3 to 10 microM increased action potential duration, and reduced maximum upstroke velocity. At concentrations of 3 and 10 microM, chloroquine increased automaticity and reduced maximum diastolic potential, and after 60 min of perfusion with a concentration 10 microM, spontaneous activity was abolished. In isolated cat ventricular myocytes, chloroquine also increased action potential duration in a concentration-dependent manner, and reduced resting membrane potential at 3 and 10 microM. In voltage-clamped cat ventricular myocytes, chloroquine blocked several inward and outward membrane currents. The order of potency was inward rectifying potassium current (I(K1)) > rapid delayed rectifying potassium current (I(Kr)) > sodium current (I(Na)) > L-type calcium current (I(Ca-L)). Only tonic block of I(Na) and I(Ca-L) was observed at a stimulation frequency of 0.1 Hz and no additional blockade was observed during stimulation trains applied at 1 Hz. The effect of chloroquine on I(K1) was voltage-dependent, with less pronounced blockade at negative test potentials. In addition, unblock was achieved by hyperpolarizing pulses to potentials negative to the current reversal potential. Chloroquine blocked the rapid component of the delayed rectifying outward current, I(Kr,) but not the slow component, I(Ks). These findings provide the cellular mechanisms for the prolonged QT interval, impaired ventricular conduction, and increased automaticity induced by chloroquine, which have been suggested as responsible for the proarrhythmic effects of the drug.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259572

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  46 in total

1.  Syncope following oral chloroquine administration in a hypertensive patient controlled on amlodipine.

Authors:  A A Leslie Ajayi; A Q Adigun
Journal:  Br J Clin Pharmacol       Date:  2002-04       Impact factor: 4.335

2.  Voltage-dependent biphasic effects of chloroquine on delayed rectifier K(+)-channel currents in murine thymocytes.

Authors:  I Kazama; Y Maruyama; Y Murata; M Sano
Journal:  J Physiol Sci       Date:  2012-02-12       Impact factor: 2.781

3.  Piperaquine Population Pharmacokinetics and Cardiac Safety in Cambodia.

Authors:  Pattaraporn Vanachayangkul; Chanthap Lon; Michele Spring; Sommethy Sok; Winita Ta-Aksorn; Chanikarn Kodchakorn; Sut-Thang Pann; Soklyda Chann; Mali Ittiverakul; Sabaithip Sriwichai; Nillawan Buathong; Worachet Kuntawunginn; Mary So; Theng Youdaline; Erin Milner; Mariusz Wojnarski; Charlotte Lanteri; Jessica Manning; Satharath Prom; Mark Haigney; Louis Cantilena; David Saunders
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

4.  Optogenetics-enabled dynamic modulation of action potential duration in atrial tissue: feasibility of a novel therapeutic approach.

Authors:  Thomas V Karathanos; Patrick M Boyle; Natalia A Trayanova
Journal:  Europace       Date:  2014-11       Impact factor: 5.214

5.  Structural basis for the antiarrhythmic blockade of a potassium channel with a small molecule.

Authors:  Yoshio Takemoto; Diana P Slough; Gretchen Meinke; Christopher Katnik; Zachary A Graziano; Bojjibabu Chidipi; Michelle Reiser; Mohammed M Alhadidy; Rafael Ramirez; Oscar Salvador-Montañés; Steven Ennis; Guadalupe Guerrero-Serna; Marian Haburcak; Carl Diehl; Javier Cuevas; Jose Jalife; Andrew Bohm; Yu-Shan Lin; Sami F Noujaim
Journal:  FASEB J       Date:  2018-01-05       Impact factor: 5.191

6.  In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials.

Authors:  Franco Borsini; William Crumb; Silvia Pace; David Ubben; Barb Wible; Gan-Xin Yan; Christian Funck-Brentano
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

7.  Structural bases for the different anti-fibrillatory effects of chloroquine and quinidine.

Authors:  Sami F Noujaim; Jeanne A Stuckey; Daniela Ponce-Balbuena; Tania Ferrer-Villada; Angelica López-Izquierdo; Sandeep V Pandit; José A Sánchez-Chapula; José Jalife
Journal:  Cardiovasc Res       Date:  2011-01-13       Impact factor: 10.787

8.  Chloroquine blocks a mutant Kir2.1 channel responsible for short QT syndrome and normalizes repolarization properties in silico.

Authors:  Angelica Lopez-Izquierdo; Daniela Ponce-Balbuena; Tania Ferrer; Frank B Sachse; Martin Tristani-Firouzi; Jose A Sanchez-Chapula
Journal:  Cell Physiol Biochem       Date:  2009-08-03

9.  Syncope in a patient being treated for hepatic and intestinal amoebiasis.

Authors:  Kavita Yelve; Sanat Phatak; Meenakshi Amit Patil; Amar R Pazare
Journal:  BMJ Case Rep       Date:  2012-11-30

10.  Action potential clamp and chloroquine sensitivity of mutant Kir2.1 channels responsible for variant 3 short QT syndrome.

Authors:  Aziza El Harchi; Mark J McPate; Yi hong Zhang; Henggui Zhang; Jules C Hancox
Journal:  J Mol Cell Cardiol       Date:  2009-03-10       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.